Compugen, Bayer deal

Compugen said it will receive the first milestone payment under an August 2013 deal with Bayer to research and develop antibody-based cancer immunotherapies against two undisclosed immune checkpoint regulators discovered by Compugen. The $1.2 million milestone was triggered by an undisclosed preclinical event for one of the immune checkpoint regulators. ...